Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI between Lobeglitazone and Empagliflozin in Healthy Males
NCT02854748Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Aug 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve from time 0 to time t at steady state at Day 5 and Maximum Plasma Concentration at steady state at Day 5. Status: unknown.
02
Drugs
lobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02854748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02854748.